A drug for prostate can delay the párkinson

Do you often change your mind? Blame it on your brain A medication used for treating prostate hyperplasia (BPH) -enlargement of the prostate gland - it can b

A drug for prostate can delay the párkinson
Do you often change your mind? Blame it on your brain

A medication used for treating prostate hyperplasia (BPH) -enlargement of the prostate gland - it can become a powerful tool for Parkinson's disease.

terazosin , which helps to relieve the symptoms of benign prostatic hyperplasia (BPH) to l relax the muscles of the bladder and the prostate , you might have a function beneficial in the brain cells damaged by Parkinson's.

According to a study published in the Journal of Clinical Investigation", the drug could delay the progression of Parkinson's, something that currently is not possible.

The researchers of University of Iowa (USA) and the Institute for Brain Disorders, Beijing (China), studied thousands of patients with BPH and párkinson . Their findings suggest that the drug alfabloqueante protects brain cells from destruction.

The párkinson is a progressive condition that affects the brain, for which currently there is no cure . Existing treatments can help with some of the symptoms , but they may not delay or reverse the loss of neurons that occurs with the disease.

The existing treatments can help with some symptoms, but cannot slow or reverse the loss of neurons that occurs with the disease.

terazosin can help by activating an enzyme called PGK1 to prevent the death of brain cells . In rodents, the drug seemed to slow down or stop the loss of nerve cells.

The study

in order To begin to assess if the drug could have the same effect on the people, searched the medical records of millions of patients with EE. UU. in order to identify the men with BPH and Parkinson's disease.

So, looked at 2,880 patients with párkinson taking terazosin or similar drugs that target PGK1, and a comparison group of 15.409 patients párkinson who took a different treatment for BPH that does not interfere on PGK1.

patients who took the drugs targeted to PGK1 seemed to get better results in terms of symptoms and progression of Parkinson's disease, which according to the researchers justified clinical trials, they plan to start this year.

Given that terazosin has a proven track record for the treatment of BPH, get it approved and ‘re-used’ as a medicine for the párkinson should be more straightforward if the clinical trials provide positive results.

Updated Date: 17 September 2019, 16:00

ABC ES

ABC ES

You need to login to comment.

Please register or login.

RELATED NEWS